RecruitingPhase 2NCT05879055
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Studying Neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biotheus Inc.
- Principal Investigator
- Jianming XuChinese PLA General Hospital
- Intervention
- PM8002(drug)
- Enrollment
- 60 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (13)
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- Fujian Province Cancer Hospital, Fuzhou, Fujian, China
- Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Jingzhou First People's Hospital, Jingzhou, Hubei, China
- Union Hospital Tongji Medical College of Hust, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- The Central Hospital of Yongzhou, Yongzhou, Hunan, China
- Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- Shandong Cancer Hospital, Jinan, Shandong, China
- Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University), Kunming, Yunnan, China
- Chinese PLA General Hospital, Beijing, China
- ZhongShan Hospital Fudan University, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05879055 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06202066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute
- RECRUITINGNCT06282016Risk Factors for Neuroendocrine NeoplasmsBavarian Cancer Registry
- RECRUITINGPHASE2NCT07077551NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06276309Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine TumorsFujian Maternity and Child Health Hospital
- RECRUITINGPHASE3NCT05918302Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.Grupo Espanol de Tumores Neuroendocrinos
- RECRUITINGNCT06402695Observational Study on GEP-and Pulm-NET Treated at FPGFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06337760YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.European Institute of Oncology
- RECRUITINGNANCT06523582Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsUniversidad Nacional Autonoma de Mexico